Rallybio Corporation (RLYB)
NASDAQ: RLYB · Real-Time Price · USD
0.3205
+0.0035 (1.10%)
May 5, 2025, 4:00 PM EDT - Market closed
Rallybio Employees
Rallybio had 25 employees as of December 31, 2024. The number of employees decreased by 18 or -41.86% compared to the previous year.
Employees
25
Change (1Y)
-18
Growth (1Y)
-41.86%
Revenue / Employee
$25,440
Profits / Employee
-$2,311,000
Market Cap
13.34M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 25 | -18 | -41.86% |
| Dec 31, 2023 | 43 | 2 | 4.88% |
| Dec 31, 2022 | 41 | 6 | 17.14% |
| Dec 31, 2021 | 35 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
RLYB News
- 6 days ago - Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference - Business Wire
- 27 days ago - Rallybio Stock Plunges After Program For Pediatric Bleeding Disorder Disappoints - Benzinga
- 27 days ago - Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT - Business Wire
- 7 weeks ago - Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - Business Wire
- 2 months ago - Rallybio to Present at the TD Cowen 45th Annual Health Care Conference - Business Wire
- 2 months ago - Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial - Business Wire
- 4 months ago - Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025 - Business Wire
- 5 months ago - Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting - Business Wire